Structural and mechanistic basis of differentiated inhibitors of the acute pancreatitis target kynurenine-3-monooxygenase
Kynurenine-3-monooxygenase (KMO) is an emerging clinical target for treatment of neurodegenerative diseases and acute pancreatitis. Here, the authors report potent inhibitors that bind KMO in an unexpected conformation, offering structural and mechanistic insights for future drug discovery ventures.
Saved in:
Main Authors: | Jonathan P. Hutchinson, Paul Rowland, Mark R. D. Taylor, Erica M. Christodoulou, Carl Haslam, Clare I. Hobbs, Duncan S. Holmes, Paul Homes, John Liddle, Damian J. Mole, Iain Uings, Ann L. Walker, Scott P. Webster, Christopher G. Mowat, Chun-wa Chung |
---|---|
Format: | article |
Language: | EN |
Published: |
Nature Portfolio
2017
|
Subjects: | |
Online Access: | https://doaj.org/article/6a2d1e05cbf54050aa6e26f4834e4b9a |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Full-length in meso structure and mechanism of rat kynurenine 3-monooxygenase inhibition
by: Shinya Mimasu, et al.
Published: (2021) -
Ablation of kynurenine 3-monooxygenase rescues plasma inflammatory cytokine levels in the R6/2 mouse model of Huntington’s disease
by: Marie Katrin Bondulich, et al.
Published: (2021) -
Kynurenine and depressive symptoms in a poststroke population
by: Bensimon K, et al.
Published: (2014) -
An ancient family of lytic polysaccharide monooxygenases with roles in arthropod development and biomass digestion
by: Federico Sabbadin, et al.
Published: (2018) -
Structural and electronic determinants of lytic polysaccharide monooxygenase reactivity on polysaccharide substrates
by: T. J. Simmons, et al.
Published: (2017)